by Manon FRACHON | 6 Dec Tue | English
The Series C extension round will accelerate clinical development, manufacturing scale-up and pre-commercialization activities of Pulmocide’s lead product candidate, opelconazole. Paris, France, December 6th 2022 – Jeito Capital (“Jeito”), the...
by Manon FRACHON | 22 Nov Tue | English
Jeito Capital co-leads oversubscribed EUR 50 million Series C financing with Brandon Capital CatalYm is developing a new class of anti-cancer immunotherapies, which have already demonstrated initial promising clinical results in advanced-stage solid tumor patients...
by Manon FRACHON | 2 Nov Wed | English
Jeito Capital participates in $120 million financing alongside ARCH Venture Partners and Monograph Capital HI-Bio is a San Francisco-based clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases Investment...
by Manon FRACHON | 25 Oct Tue | English
Bastien Renaud is appointed Chief Financial Officer Evaldo Bifulco, Head of Compliance & Risk, and Charlotte Formont, Associate Counsel, also joined Jeito Capital in 2022 Paris, France, October 26, 2022 – Jeito Capital (“Jeito”), a leading...
Recent Comments